Methods of obtaining tumor-specific T cell receptors
AssigneesSYZ Cell Therapy Co., HRYZ (Shenzhen) Biotech Co.
InventorsXiangjun Zhou, Yanyan Han, Xiaoling Liang, Xihe Chen
Life of this patent
Estimating the term…
Abstract
Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.
Claims28
A method of treating a cervical cancer comprising HPV18-E7 in an individual, comprising intravenously administering to the individual an effective amount of a pharmaceutical composition comprising an engineered immune cell comprising a tumor-specific T-cell receptor (TCR) and a pharmaceutically acceptable carrier, wherein the TCR is selected from the group consisting of the following TCRs:
- (a) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 274, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 275, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 58;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 276, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 277, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 61;
- (b) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 278, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 279, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 70;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 280, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 281, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 73;
- (c) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 282, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 283, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 76;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 284, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 285, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 79;
- (d) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 286, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 287, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 87;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 288, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 289, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 90;
- and
- e) a TCR comprising a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 290, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 291, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 93;
- and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 292, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 293, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 96.
Dependencies are inferred from the claim text.